<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491309</url>
  </required_header>
  <id_info>
    <org_study_id>Reha PH Rheumatic</org_study_id>
    <nct_id>NCT00491309</nct_id>
  </id_info>
  <brief_title>Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension</brief_title>
  <official_title>Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Patients with rheumatic disease exercise training is a well established element of
      therapy. In contrast patients with severe pulmonary hypertension are advised to avoid
      physical exertion and must not perform exercise training. This study aims to evaluate the
      effectivity and safety of a low-dose training program in patients with pulmonary hypertension
      and rheumatic disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the 6-minute walking distance</measure>
    <time_frame>after 3 weeks and after 15 weeks compared to baseline.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>baseline and 15 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in inflammatory parameters (BKS, CRP, Leucocytes), change in inflammatory cytokines (TNF-α), change in parameters of the vascular endothelium (Endothelin, PDGF, VEGF), and endothelial progenitor cells</measure>
    <time_frame>baseline and 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical capacity in the cardiopulmonary exercise testing (Watt)</measure>
    <time_frame>baseline, 3 weeks, 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of peak oxygen consumption and other parameters of cardiopulmonary exercise testing.</measure>
    <time_frame>baseline, 3 weeks, 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamic parameters: dimension and pump function of the right and the left ventricle.</measure>
    <time_frame>baseline, 15 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in systolic pulmonary arterial pressure at rest and during exercise</measure>
    <time_frame>baseline, 3 weeks, 15 weeks</time_frame>
    <description>echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of NTproBNP-value</measure>
    <time_frame>baseline, 3 weeks, 15 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Connective Tissue Disease</condition>
  <arm_group>
    <arm_group_label>exercise training group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group without exercise training</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>continuation of sedentary lifestyle without advice for specific exercise training</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise training</intervention_name>
    <description>exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)</description>
    <arm_group_label>exercise training group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent

          2. Men and women 18 - 80 years

          3. Diagnosed rheumatic disease: rheumatoid arthritis, Collagenosis (Systemic Lupus
             Erythematodes, Systemic Sclerosis, Sjögren-Syndrome, Sharp-Syndrome, Crest-Syndrome,
             Mixed connective tissue disease)

          4. Symptomatic PAH (WHO- functional class II-IV) invasively diagnosed by right heart
             catheterisation

               -  Mean pulmonary artery pressure (mPAP) &gt; 25 mmHg

               -  Pulmonary capillary wedge pressure (PCWP) &gt; 15 mmHg

               -  Pulmonary vascular resistance (PVR) at baseline &gt;320 dyn.sec/cm5 patients under
                  optimized medical treatment since at least 2 ½ months

        Exclusion Criteria:

          1. Other forms of PAH.

          2. Pregnancy or lactation

          3. Change in medication during the last 2 ½ months

          4. Patients with signs of right heart decompensation

          5. Severe impairment of walking

          6. Unclear diagnosis

          7. No invasive diagnosis of PH

          8. Acute illness, infection, fever

          9. Severe lung disease with FEV1 &lt;50% and TLC&lt; 70% below reference
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekkehard Gruenig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxclinic at the University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ekkehard Gruenig, MD</last_name>
    <phone>+49 6221 396 80 53</phone>
    <email>ekkehard.gruenig@thoraxklinik-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thoraxclinic at the University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ekkehard Gruenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>July 1, 2014</last_update_submitted>
  <last_update_submitted_qc>July 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Ekkehard Gruenig</investigator_full_name>
    <investigator_title>Prof. Dr. med. Ekkehard Grünig</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

